Neuromodulation: Spinal Cord Stimulation Devices Market

According to a recent CDC study, 20.1% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities with similar numbers being reported in Europe. In 2021, the spinal cord stimulation (SCS) devices market was worth nearly $2.9 bn. Market drivers of the SCS devices market through 2026 will be driven by an aging population and an increase in selected conditions (eg back/leg pain, and a growing number of indications) that result in debilitating and unrelenting chronic pain. Another potential area of market growth may be the Parkinson’s disease community. Should SCS technology be indicated for treating symptoms of the disease without the need of pharmaceutical intervention, the resulting growth will be substantial. Market limiters include a lack of surgeons trained in SCS implantation, adequate facilities, and the components needed to manufacture SCS devices. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for spinal cord stimulation devices for the treatment of chronic pain. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World (RoW). The forecast range for this report is 2021–26.

If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].